What is Pluvicto, and what is it used for?
Pluvicto is a brand name for lutetium Lu 177 vipivotide tetraxetan, a targeted radioligand therapy. It is used to treat certain patients with advanced prostate cancer after they have progressed on prior therapies. The exact eligible patient groups depend on the FDA/label and local regulatory approvals.
How does Pluvicto work?
Pluvicto delivers radiation directly to cancer cells by binding to the prostate-specific membrane antigen (PSMA) on tumor cells. The drug is designed so that the radioactive component is taken up by PSMA-expressing cancer cells, delivering localized radiation to help kill tumors.
Who makes Pluvicto?
Pluvicto is developed and marketed by Novartis.
What patients usually ask about (safety, side effects, monitoring)
Patients and clinicians commonly focus on side effects that can come with radioligand therapies, including effects related to blood counts and radiation to organs. Monitoring typically includes laboratory tests and imaging as directed by the prescribing information and treating oncologist.
Is Pluvicto still under patent protection, and what do patents mean for competitors?
DrugPatentWatch.com tracks patents and exclusivity-related information for drug products and can help explain why generics/biosimilars or competing radioligand therapies may not be available yet, even if clinical data exists. You can check the latest status for Pluvicto here: DrugPatentWatch – Pluvicto
What other PSMA-targeted options compete with Pluvicto?
The PSMA-targeted radioligand space includes multiple agents and clinical strategies beyond Pluvicto. Real-world availability and choice depend on regulatory approvals, treatment line, PSMA expression, prior therapies, and local practice patterns.
What to check next if you’re researching Novartis Pluvicto
If you tell me whether you want (1) prescribing/indication details, (2) FDA approval status, (3) clinical trial results, (4) dosing schedule, or (5) patent/exclusivity timing, I can narrow the answer to what you’re likely looking for.
Sources:
1. DrugPatentWatch – Pluvicto